Given the benefits shown in these studies, SGLT2 inhibitors could be considered a novel treatment strategy for PCOS as they target multiple hormonal, metabolic, and glycemic control-associated abnormalities. Here, SLC5A2 is linked to polycystic ovary syndrome.